Bioregenx (BRGX) Revenue (2022 - 2026)

Bioregenx's Revenue history runs 5 years deep, the most recent figure standing at $426175.0 for Q1 2026.

• On a quarterly basis, Revenue fell 17.27% year-over-year to $426175.0 in Q1 2026; TTM through Mar 2026 was $1.8 million, a 23.56% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 28.72% from the prior year.
• Revenue climbed to $426175.0 in Q1 2026 per BRGX's latest filing, from $381707.0 in the prior quarter.
• Across five years, Revenue topped out at $1.1 million in Q1 2023 and bottomed at $7704.0 in Q1 2022.
• The 5-year median for Revenue is $509532.0 (2025), against an average of $502382.0.
• Across the five-year window, Revenue surged 14225.69% in 2023 and sank 51.51% in 2024, its largest moves.
• Year by year, Revenue stood at $8914.0 in 2022, then surged by 10608.3% to $954538.0 in 2023, then sank by 51.51% to $462846.0 in 2024, then retreated by 17.53% to $381707.0 in 2025, then grew by 11.65% to $426175.0 in 2026.
• Per Business Quant, the three latest BRGX Revenue figures stand at $426175.0 (Q1 2026), $381707.0 (Q4 2025), and $509532.0 (Q3 2025).